Two economists are urging policymakers to test payments to families of deceased organ donors, arguing that targeted incentives could save lives and ease a worsening shortage. Their case arrives as transplant waiting lists remain long and supply falls short, placing pressure on hospitals, insurers, and grieving families alike.
The economists frame the issue as both moral and practical: more viable organs would reduce deaths and trim medical costs tied to long waits. They also point to a gap between wide public support for donation and the number of donors who actually register and follow through.
Why Supply Lags Demand
Organ donation in the United States operates under strict rules. The National Organ Transplant Act bans the purchase or sale of organs. Most donations come from deceased donors who signed up in life, or from living donors who volunteer a kidney or part of a liver. Yet demand still exceeds supply.
Health officials and transplant centers have tried many approaches to close the gap. These include public education campaigns, donor registration drives, and process reforms inside hospitals. The results have been uneven, and many candidates wait months or years for an organ.
The Argument for Compensation
“Two economists get into the business—and stakes—of organ donation, and they argue why the government should financially compensate their families.”
In their discussion, the economists say modest, transparent compensation for the families of deceased donors could raise participation without commercializing the act itself. They emphasize government-administered benefits, not private bidding, and safeguards to prevent coercion.
They also refer to earlier conversations about the shortage, including “Too many subscriptions, not enough organs” and “Your Organs, Please,” to show that the problem is persistent and policy tools remain limited.
Legal and Ethical Hurdles
Any payment plan would need to fit within federal law or be authorized by Congress. The current ban on organ sales is firm. Legal scholars have debated whether non-cash benefits, like funeral support, could comply with existing rules, but the line is narrow.
Ethicists warn that money may pressure struggling families. They fear it could shift a gift into a transaction and reduce trust in the system. Faith leaders and patient advocates also worry about fairness if benefits are set too high or designed poorly.
The economists counter that clear rules, standardized benefits, and strong oversight can reduce those risks. They propose pilot programs with independent review to measure safety, consent quality, and changes in donation rates.
What a Pilot Could Test
Policy trials, they suggest, should be modest, time-limited, and closely studied. Ideas include benefits that do not depend on bidding or organ quality and that are offered only after death is declared under strict clinical standards.
- Fixed funeral or memorial benefits paid to the family
- Tax credits that do not vary by organ type
- Charitable contributions in the donor’s name
- Automatic registration prompts with opt-out choices
These options aim to reduce pressure, avoid price signals, and keep decisions separate from end-of-life care. Researchers could track consent rates, equity across communities, and downstream transplant outcomes.
Costs, Savings, and Equity
The economists argue that even small gains in donation could pay for themselves. Transplants often reduce long-term treatment costs, especially for kidney failure patients who rely on dialysis. Fewer months on waitlists may also improve survival and quality of life.
They urge careful design to protect low-income and minority communities, who face higher rates of organ failure yet may be more exposed to financial pressure. Standardized, modest benefits available to every consenting family, they say, are more defensible than variable payouts.
What to Watch
Lawmakers in several states have floated ideas such as funeral vouchers or tax relief, but large-scale trials have not taken off. Hospital systems and organ procurement groups would need clear rules and funding to test any new approach.
Patient groups are split. Some see incentives as a practical tool to save lives now. Others prefer to expand education, improve end-of-life identification of donors, and refine hospital procedures before adding money to the process.
The economists’ message is direct: try small, safe pilots and measure results. If donation rises without harm to consent or equity, expand. If not, strengthen other reforms.
The debate is far from settled, but pressure is rising as waiting lists persist. Policymakers will face a clear question in the months ahead: should carefully designed benefits for donor families be part of the toolkit to close the gap and reduce preventable deaths?
